🇺🇸 FDA
Pipeline program

Adjuvant immunotherapy

SYSUCC-CMY-2023-04-03

Phase 3 small_molecule active

Quick answer

Adjuvant immunotherapy for Nasopharyngeal Carcinoma is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Nasopharyngeal Carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials